Onconetix, Inc. (ONCO) Key Metrics
ONCO valuation today
Trailing 12 months · as of October 17, 2026- Market cap
- $2.5M
- Enterprise value
- −$2.8M
- P/E (TTM)
- 0.0
- Forward P/E
- —
- PEG ratio
- —
- Price / sales
- 3.9
- Price / book
- 0.2
- EV / EBITDA
- —
- Dividend yield
- —
- Beta
- 2.61
ONCO key metrics, 2019–2025
Fiscal year ended December 31, 2025 · U.S. dollarsONCO returns How much profit the business earns on the capital it uses.
ONCO financial health Debt, liquidity and how easily interest is covered.
ONCO efficiency & capital use Working capital cycle and where the cash goes.
ONCO valuation history
ONCO returns on capital
Net income (ROE, ROA) or after-tax operating income (ROIC) divided by the average of the opening and closing balance.
ONCO debt vs cash
Debt includes short- and long-term borrowings and, where reported, lease liabilities.
ONCO cash returned to shareholders
ONCO price vs earnings per share
ONCO key metrics
2019–2025| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | |
|---|---|---|---|---|---|---|---|
| Valuation | |||||||
| Market capitalization | $256.0M | — | — | — | — | — | — |
| Enterprise value | $250.8M | — | — | — | — | — | — |
| Price / sales | 314.0 | — | — | — | — | — | — |
| Price / book | 16.2 | — | — | — | — | — | — |
| EV / sales | 307.6 | — | — | — | — | — | — |
| Earnings yield | −5.5% | — | — | — | — | — | — |
| Free cash flow yield | −3.8% | — | — | — | — | — | — |
| Dividend yield | 0.2% | — | — | — | — | — | — |
| Shareholder yield (dividends + buybacks) | 0.8% | — | — | — | — | — | — |
| Share price at fiscal year-end | $78.00 | $2,677.50 | $33,660.00 | $187,000.00 | — | — | — |
| Per share | |||||||
| Revenue per share | $0.25 | — | — | — | — | — | — |
| Earnings per share | −$4.28 | — | — | — | — | — | — |
| Operating cash flow per share | −$2.95 | — | — | — | — | — | — |
| Free cash flow per share | −$2.95 | — | — | — | — | — | — |
| Cash per share | $1.59 | — | — | — | — | — | — |
| Book value per share | $4.80 | — | — | — | — | — | — |
| Tangible book value per share | −$0.85 | — | — | — | — | — | — |
| Dividends per share | $0.12 | — | — | — | — | — | — |
| Capex per share | $0.00 | — | — | — | — | — | — |
| Debt per share | $0.01 | — | — | — | — | — | — |
| Shares outstanding | 3.3M | — | — | — | — | — | — |
| Returns & profitability | |||||||
| Return on equity (ROE) | −110.6% | — | — | −112.6% | −110.6% | −29.8% | −13.7% |
| Return on invested capital (ROIC) | −34.6% | −492.0% | — | — | — | −687.8% | — |
| Return on assets (ROA) | −52.8% | −101.5% | −65.7% | −91.3% | −86.6% | −29.4% | −13.5% |
| Return on tangible assets | −220.0% | — | −581.7% | −51.0% | −110.8% | −33.2% | −13.5% |
| Free cash flow margin | — | −416.9% | — | — | — | — | — |
| Financial health | |||||||
| Total debt | $48,774 | $9.4M | $9.9M | — | — | — | — |
| Cash & short-term investments | $5.2M | $646,500 | $4.6M | $25.8M | $1.9M | $4.3M | $6.1M |
| Net debt | −$5.2M | $8.8M | $5.3M | −$25.8M | −$1.9M | −$4.3M | −$6.1M |
| Debt / equity | 0.00 | 0.98 | — | — | — | — | — |
| Debt / assets | 0.00 | 0.34 | 0.11 | — | — | — | — |
| Current ratio | 0.66 | 0.05 | 0.34 | 6.69 | 1.88 | 66.94 | 79.98 |
| Quick ratio | 0.65 | 0.05 | 0.32 | 6.69 | 1.41 | 67.45 | 79.98 |
| Interest coverage | -8.4 | -40.1 | -53.7 | — | — | — | — |
| Working capital | −$3.1M | −$17.3M | −$11.4M | $22.3M | $1.4M | $4.5M | $6.0M |
| Invested capital | $10.6M | $18.4M | −$270,591 | −$3.4M | −$481,897 | $424,949 | −$52,352 |
| Tangible asset value | −$2.8M | −$17.4M | −$79.7M | $22.4M | $1.4M | $4.7M | $6.0M |
| Net current asset value | −$3.1M | −$17.6M | −$80.3M | $22.3M | $1.4M | $4.5M | $6.0M |
| Graham net-net per share | −$1.11 | — | — | — | — | — | — |
| Capital allocation | |||||||
| Dividends paid | $409,510 | $206,404 | — | — | — | — | — |
| Share buybacks (net) | $1.7M | $718 | $58,981 | $566,810 | $0 | — | — |
| Capex / revenue | 0.0% | 1.1% | 94.1% | — | — | — | — |
| Capex / depreciation | 0.00 | 0.04 | 1.25 | 1.38 | 0.39 | 3.86 | 7.85 |
| Stock-based compensation / revenue | 9.1% | 17.4% | 564.0% | — | — | — | — |
| R&D / revenue | 8.1% | 6.1% | 3,334.3% | — | — | — | — |
| SG&A / revenue | 863.9% | 445.0% | 28,650.8% | — | — | — | — |
| Efficiency | |||||||
| Days sales outstanding | 88.0 | 17.8 | 579.3 | — | — | — | — |
| Days of inventory on hand | 214.1 | 53.2 | 56.0 | — | 26,969.9 | -4,180.3 | — |
| Days payables outstanding | 5,546.5 | 1,128.4 | 1,045.8 | 56,271.8 | 24,306.2 | 5,198.2 | 11,706.1 |
| Cash conversion cycle (days) | -5,244.4 | -1,057.4 | -410.5 | — | — | — | — |
| Receivables turnover | 4.15 | 20.52 | 0.63 | 0.00 | 0.00 | 0.00 | 0.00 |
| Payables turnover | 0.07 | 0.32 | 0.35 | 0.01 | 0.02 | 0.07 | 0.03 |
| Inventory turnover | 1.70 | 6.86 | 6.51 | — | 0.01 | — | — |
| Asset turnover | 0.03 | 0.04 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Average receivables | $196,587 | $123,020 | $92,790 | $94,187 | $98,664 | $26,568 | $8,330 |
| Average payables | $2.8M | $4.5M | $3.4M | $1.0M | $325,636 | $43,522 | $18,377 |
| Average inventory | $107,020 | $214,066 | $182,026 | $378,823 | $361,323 | −$35,000 | — |
| Intangibles / total assets | 74.4% | 96.0% | 92.7% | 0.0% | 0.0% | 0.0% | 0.0% |
Computed from ONCO's annual financial statements (latest annual report filed March 13, 2026) and the closing share price on each fiscal year-end, adjusted for stock splits. Figures in U.S. dollars; data from EODHD. Averages use the opening and closing balance of each year.
ONCO valuation and financial ratios
Based on the latest twelve months, the trailing P/E is 0.0. Onconetix earned a return on equity of −110.6% and a return on invested capital of −34.6% in fiscal 2025. It ended the year with $0.0 million of debt and $5.2 million in cash and short-term investments, a net cash position of $5.2 million. It returned $2.1 million to shareholders: $0.4 million in dividends and $1.7 million in share buybacks.
See the ONCO income statement, the ONCO chart for price history, or the ONCO stock overview for the latest quote and news.
ONCO key metrics FAQ
What is Onconetix's P/E ratio?
Onconetix's trailing P/E ratio is 0.0 based on the last twelve months of earnings (as of October 17, 2026). At the end of fiscal 2025 it was —.
What is Onconetix's return on equity?
Onconetix's return on equity (ROE) was −110.6% in fiscal 2025: net income of -$14.0 million on average shareholders' equity of $12.7 million.
What is Onconetix's ROIC?
Onconetix's return on invested capital was −34.6% in fiscal 2025, using after-tax operating income divided by average debt plus equity minus cash.
How much debt does Onconetix have?
Onconetix had total debt of $0.0 million at the end of fiscal 2025, a debt-to-equity ratio of 0.00 and more cash than debt.
What is Onconetix's dividend yield?
Onconetix paid $0.4 million in dividends in fiscal 2025 ($0.12 per share), a payout ratio of —.
Does Onconetix buy back its shares?
Yes. Onconetix spent $1.7 million on net share repurchases in fiscal 2025.
What is Onconetix's free cash flow yield?
Onconetix generated -$9.7 million of free cash flow in fiscal 2025, a free cash flow yield of −3.8% on its market value at year-end ($256.0 million).
What is Onconetix's current ratio?
Onconetix's current ratio was 0.66 at the end of fiscal 2025: current assets were 0.66 times current liabilities.